BeyondSpring (BeyondSpring) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is BeyondSpring Change In Receivables?

BeyondSpring's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means BeyondSpring's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

BeyondSpring's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means BeyondSpring's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

BeyondSpring's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BeyondSpring's liquidation value for the three months ended in Dec. 2023 was $-40.27 Mil.

BeyondSpring Change In Receivables Historical Data

The historical data trend for BeyondSpring's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeyondSpring Change In Receivables Chart

BeyondSpring Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.48

BeyondSpring Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

BeyondSpring Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

BeyondSpring (NAS:BYSI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BeyondSpring's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, BeyondSpring's accounts receivable are only considered to be worth 75% of book value:

BeyondSpring's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.002	-	48.269	+	0.75 * 0	+	0.5 * 0
=	-40.27

BeyondSpring Change In Receivables Related Terms

Thank you for viewing the detailed overview of BeyondSpring's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BeyondSpring (BeyondSpring) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeyondSpring Inc (NAS:BYSI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Liberty Street, 39th Floor, New York, NY, USA, 10005

Website

https://www.beyondspringpharma.com

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.